FY2024 EPS Estimates for ICON Public Limited Increased by Analyst (NASDAQ:ICLR)

ICON Public Limited (NASDAQ:ICLR) – Equities research analysts at William Blair boosted their FY2024 earnings per share estimates for shares of ICON Public in a report issued on Thursday, July 25th. William Blair analyst M. Smock now expects that the medical research company will post earnings of $14.63 per share for the year, up from their prior estimate of $14.60. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $14.57 per share. William Blair also issued estimates for ICON Public’s Q4 2025 earnings at $4.39 EPS.

Other research analysts have also issued research reports about the company. TD Cowen boosted their target price on ICON Public from $349.00 to $373.00 and gave the company a “buy” rating in a research report on Friday, May 31st. Evercore ISI dropped their price objective on ICON Public from $350.00 to $330.00 and set an “outperform” rating for the company in a report on Friday, April 26th. Truist Financial increased their target price on ICON Public from $367.00 to $383.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Mizuho reissued a “buy” rating and set a $346.00 target price on shares of ICON Public in a research note on Thursday, April 4th. Finally, Robert W. Baird raised their price target on shares of ICON Public from $367.00 to $376.00 and gave the stock an “outperform” rating in a research note on Monday, July 8th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $352.56.

ICON Public Price Performance

ICLR stock opened at $330.51 on Monday. The stock has a market cap of $27.27 billion, a PE ratio of 40.21, a P/E/G ratio of 1.42 and a beta of 1.23. ICON Public has a 12 month low of $221.20 and a 12 month high of $347.72. The company has a 50-day moving average price of $322.64 and a 200 day moving average price of $310.27. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.75 EPS for the quarter, topping the consensus estimate of $3.68 by $0.07. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The company had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.14 billion. During the same period in the previous year, the firm earned $2.96 earnings per share. ICON Public’s quarterly revenue was up 4.1% compared to the same quarter last year.

Insider Buying and Selling

In related news, insider Brennan Brendan 26,064 shares of the company’s stock in a transaction dated Monday, July 29th. The was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 44.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Livelsberger Financial Advisory purchased a new position in shares of ICON Public in the 4th quarter worth approximately $29,000. Pinnacle Bancorp Inc. grew its holdings in ICON Public by 110.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock worth $30,000 after purchasing an additional 55 shares during the last quarter. Riverview Trust Co purchased a new stake in shares of ICON Public during the 1st quarter valued at $31,000. GAMMA Investing LLC purchased a new stake in shares of ICON Public during the 4th quarter valued at $37,000. Finally, ORG Partners LLC acquired a new stake in shares of ICON Public in the 2nd quarter worth $59,000. 95.61% of the stock is owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.